SCHEMBL22636737

SCHEMBL22636737

CC1(C)OB(c2ccc(-c3cccnc3)c(N)c2)OC1(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 6/20 0.45
LPL P06858 5/20 0.45
TDO2 P48775 1/20 0.42
BACE1 P56817 2/20 0.40
KCNH2 Q12809 1/20 0.40
PDGFRB P09619 1/20 0.40
KDR P35968 1/20 0.40
F11 P03951 2/20 0.39
MKNK1 Q9BUB5 2/20 0.39
MKNK2 Q9HBH9 2/20 0.39
MEN1 O00255 1/20 0.39
PSIP1 O75475 1/20 0.39
AXL P30530 1/20 0.39
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2A6 P11509 1/20 0.37
F2 P00734 1/20 0.37
F10 P00742 1/20 0.37
CYP11B1 P15538 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29430844 1.00 LIPG (0.45) LIPGLPLTDO2BACE1KCNH2
SCHEMBL29430631 0.84 LIPG (0.60) LIPGLPLPDGFRBKDRF11
SCHEMBL22636772 0.84 LIPG (0.60) LIPGLPLPDGFRBKDRF11
SCHEMBL2649267 0.81 LIPG (0.45) LIPGLPLTDO2BACE1PDGFRB
SCHEMBL31401337 0.81 LIPG (0.45) LIPGLPLTDO2BACE1PDGFRB
SCHEMBL22820659 0.80 PDGFRB (0.60) LIPGLPLTDO2BACE1KCNH2
SCHEMBL31642814 0.80 LIPG (0.48) LIPGLPLPDGFRBKDRF11
SCHEMBL22636619 0.79 CYP11B1 (0.42) LIPGLPLMEN1CYP2A6CYP11B1
SCHEMBL29430793 0.79 CYP11B1 (0.42) LIPGLPLMEN1CYP2A6CYP11B1
SCHEMBL5529229 0.79 LIPG (0.47) LIPGLPLBACE1KCNH2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2024-11-07 US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-11-03 US disclosed
EP-3966196-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-03-16 EP disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS CHP1, ERAP1, QSOX1 LIPG 4649/4885LPL 4757/4885TDO2 414/4885
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS ERAP1, CHP1, QSOX1 LIPG 4052/4885LPL 3957/4885TDO2 338/4885
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators ERAP1, CHP1, QSOX1 LIPG 4579/4885LPL 4728/4885TDO2 329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.